Literature DB >> 29220545

Effects of the Bidentate Ligand on the Photophysical Properties, Cellular Uptake, and (Photo)cytotoxicity of Glycoconjugates Based on the [Ru(tpy)(NN)(L)]2+ Scaffold.

Lucien N Lameijer1, Tobias G Brevé1, Vincent H S van Rixel1, Sven H C Askes1, M A Siegler2, Sylvestre Bonnet1.   

Abstract

Ruthenium polypyridyl complexes have received widespread attention as potential chemotherapeutics in photodynamic therapy (PDT) and in photochemotherapy (PACT). Here, we investigate a series of sixteen ruthenium polypyridyl complexes with general formula [Ru(tpy)(N-N)(L)]+/2+ (tpy=2,2':6',2''-terpyridine, N-N=bpy (2,2'-bipyridine), phen (1,10-phenanthroline), dpq (pyrazino[2,3-f][1,10]phenanthroline), dppz (dipyrido[3,2-a:2',3'-c]phenazine, dppn (benzo[i]dipyrido[3,2-a:2',3'-c]phenazine), pmip (2-(4-methylphenyl)-1H-imidazo[4,5-f][1,10]phenanthroline), pymi ((E)-N-phenyl-1-(pyridin-2-yl)methanimine), or azpy (2-(phenylazo)pyridine), L=Cl- or 2-(2-(2-(methylthio)ethoxy)ethoxy)ethyl-β-d-glucopyranoside) and their potential for either PDT or PACT. We demonstrate that although increased lipophilicity is generally related to increased uptake of these complexes, it does not necessarily lead to increased (photo)cytotoxicity. However, the non-toxic complexes are excellent candidates as PACT carriers.
© 2018 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA.

Entities:  

Keywords:  cancer; light; photo-activated therapy (PACT); photodynamic therapy (PDT); ruthenium

Year:  2018        PMID: 29220545      PMCID: PMC5838788          DOI: 10.1002/chem.201705388

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


Introduction

Ruthenium based anti‐cancer compounds have been investigated for several decades1 as potential alternatives to the clinically approved cisplatin. Cisplatin is associated with serious side effects such as renal toxicity, neurotoxicity, and hearing loss.2 The most thoroughly investigated ruthenium‐based anti‐cancer agents, NAMI‐A and KP1019, both reached phase II clinical trials before being abandoned.3 More recently, the tunable photophysical properties of ruthenium(II) polypyridyl complexes have been used to develop compounds combating bacterial resistance to antibiotics,4 or new photosensitizers for photodynamic therapy as an alternative to, for example, Photofrin.5 Recently, the group of McFarland have made a great step forward in this field, by entering phase I clinical trials with a RuII‐thiophene‐polypyridyl‐based photosensitizer, TLD1433.6 Simultaneously, a great interest has been shown in the development of sterically strained ruthenium(II) complexes for the light‐induced delivery of cytotoxic cargo.7 This last approach is often referred to as photo‐activated chemotherapy (PACT).3b, 8 The proof‐of‐concept for ruthenium‐based PACT was first demonstrated by Etchenique's group, who demonstrated the photorelease of the potassium channel blocker 4‐aminopyridine (4AP) from [Ru(bpy)2(4AP)2]2+ upon visible light irradiation.9 Many other examples of ruthenium complexes used as photosensitive agents releasing anticancer molecules have been developed by the group of Turro,10 Gasser,11 Glazer,12 Kodanko,13 and Bonnet.14 Following up on our initial work using thioether monodentate ligands to cage cytotoxic aqua ruthenium complexes,14b, 15 we report here a series of related chloride complexes [1 a]Cl–[8 a]Cl having the general formula [Ru(tpy)(NN)(Cl)]Cl with NN=bpy (2,2′‐bipyridine), phen (1,10‐phenanthroline), dpq (pyrazino[2,3‐f][1,10]phenanthroline), dppz (dipyrido[3,2‐a:2′,3′‐c]phenazine, dppn (benzo[i]dipyrido[3,2‐a:2′,3′‐c]phenazine), pmip (2‐(4‐methylphenyl)‐1H‐imidazo[4,5‐f][1,10]phenanthroline), pymi ((E)‐Nphenyl‐1‐(pyridin‐2‐yl)methanimine), or azpy (2‐(phenylazo)pyridine), and of their water‐soluble derivatives [Ru(tpy)(NN)(R)](PF6)2 ([1 b](PF6)2–[8 b](PF6)2), in which R=(2‐(2‐(2‐(methylthio)ethoxy)ethoxy)ethyl‐β‐d‐glucopyranoside is a thioetherglucose conjugate (Figure 1).
Figure 1

Chemical structure of the complexes used in this study. General formula [Ru(tpy)(N−N)(R)], N−N=bpy, phen, dpq, dppz, dppn, pmip, pymi or azpy. L=Cl− or L=R (2‐(2‐(2‐(methylthio)ethoxy)ethoxy)ethyl‐β‐d‐glucopyranoside).

Chemical structure of the complexes used in this study. General formula [Ru(tpy)(NN)(R)], NN=bpy, phen, dpq, dppz, dppn, pmip, pymi or azpy. L=Cl− or L=R (2‐(2‐(2‐(methylthio)ethoxy)ethoxy)ethyl‐β‐d‐glucopyranoside). On the one hand, [Ru(tpy)(bpy)(Cl)]Cl is known to be poorly cytotoxic to cancer cells.1d On the other hand, we recently demonstrated that [Ru(tpy)(dppn)(R)](PF6)2 ([5 b](PF6)2, (Figure 1) has unique phototoxic properties based on a dual mode‐of‐action involving both photosubstitution of the thioether ligand and singlet oxygen generation. In this paper, we compare the photophysical properties of all conjugates [1 b](PF6)2–[8 b](PF6)2 and of their chloride analogues [1 a]Cl–[8 a]Cl in water, and correlate them to the uptake and cytotoxicity in cancer cells. Critically, the glucose‐containing ligand L ensures that all thioetherruthenium complexes are soluble in water, allowing their photochemistry to be studied independently from the lipophilicity of the NN spectator bidentate ligand.

Results

Synthesis

Chloride complexes [1 a]Cl,16 [2 a]Cl,17 [4 a]Cl,18 [5 a]Cl,14b [7 a]Cl,19 [8 a]Cl,20 and the ligand 2‐(2‐(2‐(methylthio)ethoxy)ethoxy)ethyl‐β‐d‐glucopyranoside (R)14b were synthesized as reported previously. Complexes [3 a]Cl and [6 a]Cl were synthesized by reacting [Ru(tpy)Cl3] with the bidentate ligand dpq or pmip in the presence of triethylamine as a reducing agent. The chloride complexes [1 a]Cl–[8 a]Cl were then reacted with an excess of the thioether ligand R in the dark in water. Silica column purification of the crude complexes, followed by size exclusion chromatography, afforded the thioetherglucose ruthenium conjugates [1 b](PF6)2, [2 b](PF6)2 and [4 b](PF6)2 as orange to red solids and [8 b](PF6)2 as a purple solid. To ease purification of the pmip complex [6 b](PF6)2, the synthesis was carried out similarly to the previously reported synthesis of [5 b](PF6)2 14b by first converting the chloride precursor [5 a]Cl to the aqua species [Ru(tpy)(pmip)(H2O)](PF6)2 using AgNO3 and NH4PF6 followed by reaction of the thioether ligand with the aqua complex. Similarly, the syntheses of [3 b](PF6)2 and [7 b](PF6)2 were carried out in the presence of AgPF6 to ensure in situ conversion of the chlorido precursor into the aqua species before coordination of the thioether ligand. All chloride complexes except [4 a]Cl, [5 a]Cl and [6 a]Cl and all thioether complexes are soluble in water. As reported for the complex [Ru(tpy)(bpy)(Hmte)](PF6)2,21 all thioether complexes showed an upfield shift of the methylsulfide group to about 1.5 ppm in the 1HNMR spectra, confirming coordination of the thioether donor atom to the ruthenium center. All new compounds were characterized using NMR spectroscopy, thin layer chromatography, electronic absorption spectroscopy, high‐resolution mass spectrometry, and elemental analysis.

Crystal structures

Attempts to crystallize the glycoconjugates [1 b](PF6)2– [8 b](PF6)2 were unsuccessful and usually led to the formation of oils or colloidal suspensions. However, single crystals suitable for X‐ray diffraction analyses were obtained for [5 a]Cl, and for [3 a]PF6 and [4 a]PF6 after salt metathesis of [3 a]Cl and [4 a]Cl using aqueous NH4PF6, followed by vapor diffusion of diethyl ether in a solution of [3 a]PF6 in acetone or acetone in a solution of [4 a]PF6 in ethyl acetate (Figure 2). The three crystal structures showed the expected distorted octahedral geometry, with a reduced (<180°) NRuN angle for the coordinated terpyridine ligand (N1‐Ru1‐N3, 159.11–159.40°, Table 1). The bidentate ligands dpq, dppz and dppn are all bound perpendicular to tpy, with a N4‐Ru1‐N5 bite angle of 79.26–80.2° (Table 1). The Ru1−Cl1 bond lengths were found to be similar with values ranging from 2.4015 to 2.4165 Å which are very close to reported values for related complexes.22 Selected bond lengths and angles are given in Table 1.
Figure 2

Displacement ellipsoid plots (50 % probability level) of the complex cation [3 a]PF6, [4 a]PF6.(CH3)2CO and [5 a]Cl at 110(2) K. For [5 a]Cl only one of the independent molecules is shown. Hydrogen atoms, counter‐ions, and lattice solvent molecules, have been omitted for clarity.

Table 1

Selected bond lengths [Å] and bond angles [°] for complexes [3 a]PF6, [4 a]PF6.(CH3)2CO and [5 a]Cl.

[3 a](PF6)2 [4 a](PF6)2 [5 a]Cl[a]
Ru1−Cl12.4062(5)2.4015(7)2.4165(17)
Ru1−N12.069(2)2.053(2)2.048(5)
Ru1−N21.9569(19)1.957(2)1.953(5)
Ru1−N32.058(2)2.064(2)2.050(5)
Ru1−N42.046(2)2.044(2)2.043(5)
Ru1−N52.0917(19)2.074(2)2.073(5)
C5−C61.472(3)1.469(4)1.469(9)
C5−N11.369(3)1.372(3)1.389(8)
C6−N21.355(3)1.357(3)1.340(7)
C10−C111.478(3)1.479(4)1.484(8)
C10−N21.355(3)1.349(4)1.340(7)
C11−N31.371(3)1.372(3)1.384(7)
C20−C211.446(3)1.440(4)1.459(8)
C20−N41.370(3)1.371(3)1.370(7)
C21−N51.364(3)1.362(3)1.379(8)
N1‐Ru1‐N3159.10(8)159.58(9)159.67(19)
N4‐Ru1‐N579.45(8)79.26(9)80.2(2)

[a] Values for Ru1Å.

Displacement ellipsoid plots (50 % probability level) of the complex cation [3 a]PF6, [4 a]PF6.(CH3)2CO and [5 a]Cl at 110(2) K. For [5 a]Cl only one of the independent molecules is shown. Hydrogen atoms, counter‐ions, and lattice solvent molecules, have been omitted for clarity. Selected bond lengths [Å] and bond angles [°] for complexes [3 a]PF6, [4 a]PF6.(CH3)2CO and [5 a]Cl. [a] Values for Ru1Å.

Photophysical properties of the [Ru(tpy)(NN)(L)] complexes

The photophysical properties of chloride complexes [1 a]Cl– [8 a]Cl were first investigated in acetonitrile, in which the complexes are all soluble and do not hydrolyze. The chloride complexes [1 a]Cl–[8 a]Cl show a 1MLCT bands varying between 501 and 523 nm, with molar absorptivities ranging from 9.1×103 to 12.8×103  m −1 cm−1 (Table 2), comparable to reported values for ruthenium(II) polypyridyl complexes.7, 12, 15, 23 All complexes have very low phosphorescence quantum yields (Φ p<10−4) except for [2 a]Cl, [5 a]Cl, and [6 a]Cl that are weakly emissive (Φ p=10−3 to 10−4). The 1O2 generation quantum yield in CD3OD are low (Φ Δ ≤0.05), with the exception of [6 a]Cl (Φ =8.2×10−2), which is also the most emissive complex.
Table 2

Lowest‐energy absorption maxima [λ max], molar absorption coefficients at λ max [ϵ max in M−1 cm−1] and λ450 [ϵ 450 in M−1 cm−1], photosubstitution quantum yields [Φ450] at 298 K, 1O2 quantum yields [ΦΔ] at 293 K, photosubstitution reactivity [ξ=Φ450 x ϵ 450], and phosphorescence quantum yield [ΦP] at 293 K for complexes [1 a]Cl–[8 a]C and, [1 b](PF6)2–[8 b](PF6)2.

Complex λ max [nm](ϵ max [M−1  cm−1])[a] ϵ 450 [M−1  cm−1]Φ450 [b] ξΦΔ [c] ΦP [c]
[1 a]Cl504 (9.1×103 )4.6×103 0.055<1×10−5
[2 a]Cl501 (9.1×103)6.5×103 0.0488.5×10−4
[3 a]Cl504 (9.1×103)6.6×103 0.055<1×10−5
[4 a]Cl511 (9.6×103)5.6×103 0.005<1×10−5
[5 a]Cl498 (12.0×103)8.5×103 0.0234.3×10−4
[6 a]Cl501 (1.12×103)6.8×103 0.0823.2×10−3
[7 a]Cl523 (13.0×103)3.4×103 0.0121.4×10−5
[8 a]Cl508 (12.2×103)3.9×103 <0.0011.8×10−5
[1 b](PF6)2 450 (7.0×103)7.0×103 0.0084590.020 (0.020)<1×10−5
[2 b](PF6)2 448 (6.2×103)6.2×103 0.0065400.050 (0.080)1.2×10−4
[3 b](PF6)2 448 (8.9×103)8.9×103 0.0067600.030 (0.010)<1×10−5
[4 b](PF6)2 458 (13.1×103)12.8×103 0.0202560.0010 (0.0030)<1×10−5
[5 b](PF6)2 458 (11.6×103)11.4×103 0.00095110.71/(0.41)<1×10−5
[6 b](PF6)2 460 (11.0×103)10.4×103 0.0070730.0020<1×10−5
[7 b](PF6)2 472 (11.7×103)11.7×103 0.0053620. 11 (0.14)2.5×10−3
[8 b](PF6)2 505 (7.2×103)2.7×103 0.0070(−)<1×10−5

[a In MeCN for [1 a]Cl–[8 a]Cl and in MilliQ H2O for [1 b](PF6)2–[8 b](PF6)2. [b] in H2O. λirr=450 nm for [1 b](PF6)2–[6 b](PF6)2 and 470 nm for [7 b](PF6)2. [c] in CD3OD.

Lowest‐energy absorption maxima [λ max], molar absorption coefficients at λ max [ϵ max in M−1 cm−1] and λ450 [ϵ 450 in M−1 cm−1], photosubstitution quantum yields [Φ450] at 298 K, 1O2 quantum yields [ΦΔ] at 293 K, photosubstitution reactivity [ξ=Φ450 x ϵ 450], and phosphorescence quantum yield [ΦP] at 293 K for complexes [1 a]Cl–[8 a]C and, [1 b](PF6)2–[8 b](PF6)2. [a In MeCN for [1 a]Cl–[8 a]Cl and in MilliQ H2O for [1 b](PF6)2–[8 b](PF6)2. [b] in H2O. λirr=450 nm for [1 b](PF6)2–[6 b](PF6)2 and 470 nm for [7 b](PF6)2. [c] in CD3OD. The hydrophilicity of the thioether analogues [1 b](PF6)2–[8 b](PF6)2 allowed for studying photosubstitution quantum yields in MilliQ water using electronic absorption spectroscopy. Monochromatic blue light (450 or 470 nm) was used to irradiate the complexes in their 1MLCT absorption band. Although all thioether complexes are thermally stable at room temperature, seven of the eight complexes, that is, [1 b](PF6)2 to [7 b](PF6)2, showed light‐induced exchange of their thioether ligand for H2O. The ligand photosubstitution was characterized by clear isosbestic points in the UV/Vis spectra (450 to 476 nm depending on the compound), as shown in Figure 3. For each of these reactions a bathochromic shift of the 1MLCT band was observed, which is consistent with earlier reports on the formation of monoaqua‐ruthenium complexes in aqueous solution.15a Most complexes have a photosubstitution quantum yield (Φ 450) of 0.5–2 percent, leading to photosubstitution reactivities (ξ=Φ450 ϵ 450, in which ϵ 450 is the molar absorption at 450 nm) on the order of ten to hundreds (ξ=11–256). Changing the bidentate ligand has thus a significant influence on the photosubstitution rates. Interestingly, the dppz complex [4 b]2+ has the highest photosubstitution quantum yield of the series, which is also about 20‐fold higher (Φ 450=0.020) than that of the structurally similar dppn analogue [5 b]2+, which showed the lowest Φ 450 (0.00095).14b Furthermore, [4 b]2+ produces minimal amounts of 1O2 (Φ=0.0010) and is poorly emissive (Φ P=<1×10−5), which indicates that contrary to the dppn complex [5 b]2+ for which light irradiation leads to low‐lying 3ππ* excited states located on the spectator bidentate ligand,14b with the dppz complex such 3ππ* states are either too high in energy to be populated, or outcompeted by a rather quick conversion to the photodissociative metal‐centered triplet state (3MC).
Figure 3

Electronic absorption spectra of [1 b](PF6)2–[4 b](PF6)2, [6 b](PF6)2 and [7 b](PF6)2 in deoxygenated H2O upon irradiation at 450 or 470 nm for 5 min at T=298 K. Spectra measured every 30 s. a) [1 b](PF6)2, [Ru]tot=1.38×10−4  m, λexc=450 nm, photon flux=1.71×10−7 mol s−1. b) [2 b](PF6)2, [Ru]tot=1.15×10−4  m, λexc=450 nm, photon flux=6.83×10−8 mol s−1. c) [3 b](PF6)2, [Ru]tot=7.91×10−5  m, λexc=450 nm, photon flux=5.29×10−8 mol s−1. d) [4 b](PF6)2, [Ru]tot=8.66×10−5  m, λexc=450 nm, photon flux=2.84×10−8 mol s−1. e) [6 b](PF6)2, [Ru]tot=4.75×10−5  m, λexc=450 nm, photon flux=4.97×10−8 mol s−1. f) [7 b](PF6)2, [Ru]tot=8.88×10−5  m, λexc=470 nm, photon flux=1.52×10−7 mol s−1. Inset depicts the evolution of ln [Ru]SRR′/[Ru]tot vs. irradiation time in s, in which [Ru]SRR represents the concentration of ruthenium‐thioether complex at time t, and [Ru]tot the total ruthenium concentration.

Electronic absorption spectra of [1 b](PF6)2–[4 b](PF6)2, [6 b](PF6)2 and [7 b](PF6)2 in deoxygenated H2O upon irradiation at 450 or 470 nm for 5 min at T=298 K. Spectra measured every 30 s. a) [1 b](PF6)2, [Ru]tot=1.38×10−4  m, λexc=450 nm, photon flux=1.71×10−7 mol s−1. b) [2 b](PF6)2, [Ru]tot=1.15×10−4  m, λexc=450 nm, photon flux=6.83×10−8 mol s−1. c) [3 b](PF6)2, [Ru]tot=7.91×10−5  m, λexc=450 nm, photon flux=5.29×10−8 mol s−1. d) [4 b](PF6)2, [Ru]tot=8.66×10−5  m, λexc=450 nm, photon flux=2.84×10−8 mol s−1. e) [6 b](PF6)2, [Ru]tot=4.75×10−5  m, λexc=450 nm, photon flux=4.97×10−8 mol s−1. f) [7 b](PF6)2, [Ru]tot=8.88×10−5  m, λexc=470 nm, photon flux=1.52×10−7 mol s−1. Inset depicts the evolution of ln [Ru]SRR′/[Ru]tot vs. irradiation time in s, in which [Ru]SRR represents the concentration of rutheniumthioether complex at time t, and [Ru]tot the total ruthenium concentration. Another interesting observation concerned the difference in reactivity between [7 b]2+ and [8 b]2+. Whereas [7 b]2+ displayed ligand dissociation efficiency comparable to that of the bpy complex [1 b]2+, the azpy compound [8 b]2+ did not show any ligand photosubstitution, indicating a strong electronic effect of the azo ligand on the photoreactivity of its ruthenium complex. The 1MLCT absorption maximum for [8 b]2+ is significantly lower in energy (505 nm) than that of [7 b]2+ (472 nm), which points to the low energy of the azo‐based π* orbital of the azpy ligand, leading to a low‐lying 3MLCT state for the complex. Considering that there is no steric strain in this complex to lower the 3MC state,23b the 3MC‐3MLCT energy gap is very large in [8 b]2+, therefore preventing photosubstitution reactions to occur. It should be noted that [8 b]2+ is not emissive at all (ΦP<1×10−5) and has a negligible 1O2 generation quantum yield (0.007), and thus that non‐radiative decay is the main deactivation pathway for this complex. Regarding singlet oxygen generation, most of the other complexes produced small amounts of 1O2 in CD3OD (Φ =0.002–0.14), with the exception of [5 b]2+ that has a very high 1O2 quantum yield of 0.71.14b Interestingly, its chloride analogue [5 a]+ only has a 1O2 quantum yield of 0.023 under the same conditions, emphasizing the critical influence of the monodentate ligand on the photochemical and dioxygen photosensitizing properties of this family of complexes.

Cytotoxicity

The cytotoxic properties of the chloride complexes [1 a]Cl‐[8 a]Cl and their caged analogues [1 b](PF6)2–[8 b](PF6)2 were evaluated against two different human cell lines: A549 (human lung carcinoma) and MCF‐7 (human breast adenocarcinoma). Considering the photo‐substitution properties of some of these complexes, their photocytotoxicity was also tested under blue light irradiation (3.2±0.2 J cm−2 at 454±11 nm), as described previously for [5 b](PF6)2.14b Cells were seeded at t=0, treated after 24 h with a concentration gradient of each ruthenium complex, irradiated or maintained in the dark after replacing the media, and further incubated in the dark for 48 h. At t=96 h cell viability was determined using the sulforhodamine B (SRB) assay.24 The effective concentrations (EC50), defined as the concentration at which a 50 % survival rate on cell viability is observed, are reported in Table 3. Most chloride complexes were found to be non‐cytotoxic, with the exception of [8 a]Cl that was found moderately cytotoxic (EC50=28 μm) against the MCF‐7 cell line, in agreement with the value reported by Reedijk and co‐workers.25 The values for [4 a]Cl (59 μm and 34 μm against A549 and MCF‐7, respectively) were found similar to that observed for [Ru(bpy)(dppz)2]2+ analogues reported by the group of Schatzschneider.26 Based on their results, it was expected that the structurally similar but more lipophilic dppn complex [5 a]Cl would be cytotoxic, but no significant toxicity was observed for this complex. On the other hand, its EC50 could not be clearly determined due to the poor solubility of this complex in cell culture medium.14b Interestingly however, [5 a]Cl was to be found cytotoxic upon blue light irradiation, with EC50 values of 9.7 and 3.2 μm for A549 and MCF‐7 cells, respectively, corresponding to photoindexes (PI) of more than 2.6 and 7.9, respectively. This result is unexpected, because the 1O2 quantum yield of [5 a]Cl (0.023) is much lower than that of its glycoconjugated analogue [5 b](PF6)2 (0.71). A possible explanation would be the partial conversion, after uptake, of the chloride complex to its aquated counterpart [Ru(tpy)(dppn)(H2O)]2+ (Figure 4 a), which has been demonstrated to be a good 1O2 sensitizer (its close analogue [Ru(toy)(dppn)(CD3OD)]2+ has a 1O2 production quantum yield under air of Φ=0.43).14b An alternative explanation would be that a different type of PDT is occurring, such as PDT type I, which is dependent upon the formation of radical species without intervention of molecular oxygen.27 Further studies would be needed to conclude on the biological mechanism of the photocytoxicity of [5 a]Cl.
Table 3

Cytotoxicity of compounds [1 a]Cl–[8 a]Cl and [1 b](PF6)2–[8 b](PF6)2 towards A549 and MCF‐7 cells in the dark and upon blue light irradiation (454 nm, 3.2 J cm‐2). Cell‐growing inhibition effective concentrations (EC50) are reported in μm with 95 % confidence interval (CI) in μm. Data is the mean over three independent experiments. Photocytotoxicity index (PI)=EC50dark/EC50light (dimensionless).

Complex[a] Light dose[J cm‐2]A549EC50 CIPIMCF‐7EC50 CIPI
[1 a]Cl0>100>100
3.2>100>100
[2 a]Cl0>10064+121.2
− 9.1
3.2>10052+15
− 10
[3 a]Cl0>100>100
3.2>100>100
[4 a]Cl059+311.334+6.01.1
− 21− 5.1
3.247+1931+4.8
− 13− 4.2
[5 a]Cl0>25>2.6>25>7.9
3.29.7+4.43.2+1.3
− 2.6− 0.87
[6 a]Cl0>25>25
3.2>25>25
[7 a]Cl0>100>100
3.2>100>100
[8 a]Cl0>10028+4.9
− 4.2
3.2
[1 b](PF6)2 0>100>100
3.2>100>100
[2 b](PF6)2 0>100>100
3.2>100>100
[3 b](PF6)2 0>100>100
3.2>100>100
[4 b](PF6)2 0>100>100
3.2>100>100
[4 b](PF6)2 [c] 064+172.452+122.6
− 13− 9.4
3.227+6.420+2.5
− 5.2− 2.2
[5 b](PF6)2 [d] 019+4.0269.6+2.911
− 3.3− 2.3
3.20.72+0.160.86+0.21
− 0.13− 0.17
[6 b](PF6)2 0>100>100
3.2>100>100
[7 b](PF6)2 0>100>100
3.2>100>100
[8 b](PF6)2 0>100>100
3.2>100>100

[a] Standard protocol: Cells were incubated with compound for 24 h, followed by replacement of the media, kept in the dark, or irradiated with blue light (5 min at 454 nm, 10.5 mW cm−2, 3.2 J cm−2) and further incubated in the dark for 48 h. [b] As in standard protocol, but without replacing media during treatment (cells are irradiated in the presence of compound). [c] Ref. 14b.

Figure 4

Proposed mechanisms for light‐induced toxicity for a) [5 a]Cl with media replacement, and b) [4 b](PF6)2 without media replacement. The lipid bilayer represents the cell membrane.

Cytotoxicity of compounds [1 a]Cl–[8 a]Cl and [1 b](PF6)2–[8 b](PF6)2 towards A549 and MCF‐7 cells in the dark and upon blue light irradiation (454 nm, 3.2 J cm‐2). Cell‐growing inhibition effective concentrations (EC50) are reported in μm with 95 % confidence interval (CI) in μm. Data is the mean over three independent experiments. Photocytotoxicity index (PI)=EC50dark/EC50light (dimensionless). [a] Standard protocol: Cells were incubated with compound for 24 h, followed by replacement of the media, kept in the dark, or irradiated with blue light (5 min at 454 nm, 10.5 mW cm−2, 3.2 J cm−2) and further incubated in the dark for 48 h. [b] As in standard protocol, but without replacing media during treatment (cells are irradiated in the presence of compound). [c] Ref. 14b. Proposed mechanisms for light‐induced toxicity for a) [5 a]Cl with media replacement, and b) [4 b](PF6)2 without media replacement. The lipid bilayer represents the cell membrane. None of the glycoconjugated complexes were found to be photocytotoxic except [5 b](PF6)2, which was recently reported to enter passively into the cells and to destroy mitochondrial DNA by singlet oxygen generation.14b In our standard treatment protocol, media is replaced before light irradiation. In such conditions, photocytotoxicity can solely rely on the molecules that have been taken up by the cells during incubation, which may be a problem for highly hydrophilic glucose‐conjugates such as [1 b](PF6)2–[8 b](PF6)2 (see below). For compound [4 b](PF6)2, an adjustment of the protocol, consisting in irradiating the cells without media refreshing, led to a modest but clearly improved PI (2.4 and 2.6 for MCF‐7 and A549, respectively). With such a protocol the full dose of compound added to each well remains present during and after irradiation, and most importantly activation may occur outside the cell, and be followed by cellular uptake of the activated photoproduct. For [4 b](PF6)2, the observed phototoxicity might thus be explained by the formation of the aquated species [Ru(tpy)(dppz)(H2O)]2+ outside the cell, followed by in situ conversion to the chloride species [4 a]Cl due to the high chloride content in media (>100 mm), followed by cellular uptake (Figure 4 b). This interpretation is supported by the EC50 values found for [4 a]Cl, which were not impressive but could clearly be measured (59 and 34 μm for A549 and MCF‐7 respectively). Not refreshing the media before light activation did not lead to enhanced toxicity for [1 b](PF6)2–[3 b](PF6)2 and for [6 b](PF6)2–[7 b](PF6)2, showing that keeping high concentrations of the prodrug during and after light irradiation does not necessarily lead to enhanced phototoxicity. Overall, these results demonstrate that [4 b](PF6)2 is a moderately effective PACT agent,3b whereas the dppn analogues [5 a]Cl and [5 b](PF6)2 are catalytic PDT sensitizers, which can be activated using a low dose of blue light. They also demonstrate that apparently minor differences in the treatment protocol of light‐activated drugs may lead to very different interpretation of the cytotoxicity of light‐activated compounds.

Log P o/w and uptake

To acquire more insight on the effect of glycoconjugation on the solubility, cellular uptake, and toxicity of these complexes, the water‐octanol partition coefficients (log P o/w) were determined for all complexes according to reported standards (Figure 5 b).28 As shown in Figure 5 b (left), the chloride compounds with the smallest bidentate ligands, that is, [1 a]Cl–[3 a]Cl, have similar log P o/w values ranging from −0.81 to −1.1, while [7 a]Cl and [8 a]Cl have log P o/w values of −1.60 to −1.80. For these five complexes, the chloride counter anion provides appreciable water solubility. By contrast, the chloride compounds with the largest bidentate ligands, that is, [4 a]Cl–[6 a]Cl, are much more hydrophobic with log P o/w values ranging from −0.10 to +1.0. Although one may expect that the dicationic nature of [1 b](PF6)2–[8 b](PF6)2 and glycoconjugation should necessarily improve water solubility compared to their chloride analogues, we found that [1 b](PF6)2–[3 b](PF6)2 had similar log P o/w values (−0.11 to −0.51, respectively) compared to their analogues [1 a]Cl–[3 a]Cl, whereas [7 b](PF6)2 and [8 b](PF6)2 were slightly more hydrophobic (log P =−0.20 and −0.18, respectively) than [7 a]Cl and [8 a]Cl. This result points to the critical influence of the counterions, as the two hexafluoridophosphate anions of the glycoconjugate compounds increase lipophilicity, compared to chlorides. Furthermore, the chloride complexes are not stable in water, resulting in (partial) conversion to the [Ru(tpy)(NN)(H2O)]Cl2 species which are more soluble in water than the hexafluoridophosphate salts of the R‐substituted ruthenium complexes. The most hydrophobic chloride complexes [4 a]Cl–[6 a]Cl, that were much more difficult to dissolve in water, profited most from the glycoconjugation because [4 b](PF6)2–[6 b](PF6)2 indeed became water soluble (log P =−0.84 to −0.50, respectively). Overall glycoconjugation allowed for investigating the photochemistry of all thioether complexes [1 b](PF6)2–[8 b](PF6)2 in water.
Figure 5

Intracellular uptake of 25 μM of [1 a]Cl–[8 a]Cl (left) and [1 b]‐[8 b](PF6)2 (right) in A549 cells after 24 h. Values are reported ± SD, n=2. b) Log P o/w values found for [1 a]Cl‐‐[8 a]Cl (left) and [1 b](PF6)2–[8 b](PF6)2 (right). Values are reported ±SD, n=3.

Intracellular uptake of 25 μM of [1 a]Cl–[8 a]Cl (left) and [1 b]‐[8 b](PF6)2 (right) in A549 cells after 24 h. Values are reported ± SD, n=2. b) Log P o/w values found for [1 a]Cl‐‐[8 a]Cl (left) and [1 b](PF6)2–[8 b](PF6)2 (right). Values are reported ±SD, n=3. To check whether the low toxicity of the thioetherglucose conjugates was not simply due to a low uptake, cellular uptake was studied for all sixteen complexes in A549 cells at a concentration of 25 μm, using an incubation time of 24 h and measuring intracellular ruthenium concentrations by ICP‐MS. Although no general correlation could be found between the log P o/w values for these complexes and their cellular uptake, very strong differences in metal uptake were observed depending on the ligands and counterions (Figure 5 a). The most hydrophobic chloride compounds [4 a]Cl, [5 a]Cl and [6 a]Cl displayed very high metal uptake (>1000 ng Ru per million cells), whereas their glycoconjugates [4 b](PF6)2, [5 b](PF6)2 and [6 b](PF6)2 displayed cellular uptake that was much lower (10–20 ng Ru per million cells, for example, 250 times lower for [5 b](PF6)2 compared to [5 a]Cl). Of course, this lower uptake can partially be explained by the lower log P o/w values of the glycoconjugates, and at least for [5 b](PF6)2, by the absence of GLUT‐based active uptake.14b However, [4 b](PF6)2–[6 b](PF6)2 are also taken up in 10‐fold higher amounts than [1 b](PF6)2–[3 b](PF6)2, which have comparable log P o/w values. These results may not necessarily represent the conditions experienced by these compounds at the cell membrane, for which it is more likely that the lipophilic PF6 − counterions are already exchanged for the more abundant and more water soluble chloride or phosphate anions in the buffer, canceling the effect of the PF6 − anion on lipophilicity.

Discussion

Some of the chloride complexes [1 a]Cl–[8 a]Cl were thermally unstable and therefore no photodissociation quantum yields were determined, whereas their singlet oxygen properties were in general very low. The phototoxicity in the series of the most lipophilic compounds [4 a]Cl–[6 a]Cl cannot be explained by the trends observed in cell uptake and singlet oxygen generation. [6 a]Cl has indeed a higher singlet oxygen quantum yield (0.082) than [4 a]Cl and [5 a]Cl (0.005 and 0.023, respectively), but it is not phototoxic, whereas [4 a]Cl and [5 a]Cl are, and all three complexes are taken up in high amounts. In this series of complexes, different intracellular localization or biological targets, coupled to unknown photoreactions of [5 a]Cl, must explain the differences in phototoxicity between [6 a]Cl on the one hand and [4 a]Cl and [5 a]Cl on the other. An opposite conclusion can be drawn for the glycoconjugates series [4 b](PF6)2, [5 b](PF6)2 and [6 b](PF6)2. The only phototoxic agent of this series, [5 b](PF6)2, has by far the highest singlet oxygen quantum yield (0.71 vs. 0.0010 and 0.0020), whereas all three compounds are taken up in similar amounts (10–20 ng Ru per million cell). Hence, [5 b](PF6)2 is at least an excellent PDT agent, whereas a PACT mode of action cannot be ruled out considering the phototoxic properties of [5 a]Cl and its low singlet oxygen quantum yield. The phototoxicity observed for [4 b](PF6)2 when the protocol is slightly modified, suggests that this compound may act as a cytotoxic PACT agent. Furthermore [4 b](PF6)2 showed the highest photosubstitution quantum yield (0.02) and no significant singlet oxygen production. When cell‐culture media was replaced before light irradiation, the glycoconjugate compound was not taken up in high amounts, and given the poor photodynamic properties of the photoproduct ([4 a]+ or [Ru(tpy)(dppz)(OH2)]2+) not enough reactive oxygen species could be generated to kill the cells. This example demonstrates that the potential of [4 b](PF6)2 as a PACT agent is determined by the treatment protocol, which should be taken into account in further PACT studies. Furthermore, this complex has been shown to act has a DNA light‐switch in the presence of DNA, which might be useful for theranostic applications.29

Conclusion

Overall eight chloride terpyridine complexes [1 a]Cl–[8 a]Cl with eight different bidendate spectator chelating ligands, and their eight thioetherglucose conjugates, were synthesized to compare the corresponding photophysical properties, photoreactivity, water solubility, cellular uptake, and phototoxicity. Depending on the bidentate ligand, these complexes can be considered either for photocaging, or for PACT and/or PDT. Compound [8 a]Cl is not suitable for photocaging or phototherapy because the azo group of the azpy spectator ligand stabilizes the 3MLCT states too much and prevents thermal population of the 3MC state, thereby quenching photosubstitution. Singlet oxygen generation was also fully quenched in [8 a]Cl and [8 b](PF6)2, emphasizing the poor photosensitizing properties of this compound. The five complexes [1 a]Cl–[3 a]Cl, [6 a]Cl, and [7 a]Cl, are non‐toxic, and once substituted by thioethers, they form complexes with similar photosubstitution quantum yields (Φ450 ≈0.01) and low 1O2 production quantum yields (ΦΔ<0.10). As a consequence, they are excellent candidates for the photocaging of thioether‐based biologically active compounds, such as the antibiotics amoxicillin and clindamycin. The exceptionally high cellular uptake measured for [6 a]Cl is worth noticing (5220±737 ng Ru per million cells), considering that this compound did not show any measurable cytotoxicity at concentrations lower than 25 μm. It can even turn highly hydrophilic compounds such as R into species such as [6 b](PF6)2 that are still lipophilic enough to enter into cancer cells. Finally, [4 a]Cl and [5 a]Cl show similar lipophilicity compared to [6 a]Cl and comparably high cellular uptake, but they also showed some toxicity both in the dark and after light activation. They are therefore less interesting as PACT carriers and instead have better potential as a either a cytotoxic PACT agent or for PDT, as we have recently demonstrated for [5 b](PF6)2. 14b Overall, this work demonstrates that complexes based upon the [Ru(tpy)(NN)(R)] scaffold are good photocaging agents but poorly (photo)cytotoxic unless DNA intercalators such as dppz and dppn are chosen as a bidentate ligand, in which case they could serve as phototoxic agents.

Conflict of interest

The authors declare no conflict of interest. As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re‐organized for online delivery, but are not copy‐edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors. Supplementary Click here for additional data file.
  35 in total

1.  A novel class of ruthenium-based photosensitizers effectively kills in vitro cancer cells and in vivo tumors.

Authors:  Jamie Fong; Kamola Kasimova; Yaxal Arenas; Pavel Kaspler; Savo Lazic; Arkady Mandel; Lothar Lilge
Journal:  Photochem Photobiol Sci       Date:  2015-11       Impact factor: 3.982

2.  N-acetylmethionine and biotin as photocleavable protective groups for ruthenium polypyridyl complexes.

Authors:  Roosmarijn E Goldbach; Isabel Rodriguez-Garcia; Joop H van Lenthe; Maxime A Siegler; Sylvestre Bonnet
Journal:  Chemistry       Date:  2011-07-27       Impact factor: 5.236

3.  Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy.

Authors:  Suzanne Leijen; Sjaak A Burgers; Paul Baas; Dick Pluim; Matthijs Tibben; Erik van Werkhoven; Enzo Alessio; Gianni Sava; Jos H Beijnen; Jan H M Schellens
Journal:  Invest New Drugs       Date:  2014-10-25       Impact factor: 3.850

Review 4.  The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials.

Authors:  Leli Zeng; Pranav Gupta; Yanglu Chen; Enju Wang; Liangnian Ji; Hui Chao; Zhe-Sheng Chen
Journal:  Chem Soc Rev       Date:  2017-10-02       Impact factor: 54.564

5.  Correlation between cytotoxicity and DNA binding of polypyridyl ruthenium complexes.

Authors:  O Nováková; J Kaspárková; O Vrána; P M van Vliet; J Reedijk; V Brabec
Journal:  Biochemistry       Date:  1995-09-26       Impact factor: 3.162

6.  Light-activated ruthenium complexes photobind DNA and are cytotoxic in the photodynamic therapy window.

Authors:  Erin Wachter; David K Heidary; Brock S Howerton; Sean Parkin; Edith C Glazer
Journal:  Chem Commun (Camb)       Date:  2012-10-07       Impact factor: 6.222

Review 7.  Critical Overview of the Use of Ru(II) Polypyridyl Complexes as Photosensitizers in One-Photon and Two-Photon Photodynamic Therapy.

Authors:  Franz Heinemann; Johannes Karges; Gilles Gasser
Journal:  Acc Chem Res       Date:  2017-10-23       Impact factor: 22.384

8.  Photodegradation of methyl orange and photoinactivation of bacteria by visible light activation of persulphate using a tris(2,2'-bipyridyl)ruthenium(II) complex.

Authors:  Gokulakrishnan Subramanian; Priyadarshini Parakh; Halan Prakash
Journal:  Photochem Photobiol Sci       Date:  2012-11-26       Impact factor: 3.982

9.  Ruthenium polypyridyl complexes and their modes of interaction with DNA: is there a correlation between these interactions and the antitumor activity of the compounds?

Authors:  Eva Corral; Anna C G Hotze; Hans den Dulk; Anna Leczkowska; Alison Rodger; Michael J Hannon; Jan Reedijk
Journal:  J Biol Inorg Chem       Date:  2008-12-16       Impact factor: 3.358

10.  Chemical Swarming: Depending on Concentration, an Amphiphilic Ruthenium Polypyridyl Complex Induces Cell Death via Two Different Mechanisms.

Authors:  Bianka Siewert; Vincent H S van Rixel; Eva J van Rooden; Samantha L Hopkins; Miriam J B Moester; Freek Ariese; Maxime A Siegler; Sylvestre Bonnet
Journal:  Chemistry       Date:  2016-07-04       Impact factor: 5.236

View more
  4 in total

1.  Synthesis, characterization and antitumor mechanism investigation of ruthenium(II) polypyridyl complexes with artesunate moiety.

Authors:  Bi-Chun Chen; Jun-Jian Lu; Ning Jiang; Xiu-Rong Ma; Rong-Tao Li; Rui-Rong Ye
Journal:  J Biol Inorg Chem       Date:  2021-09-20       Impact factor: 3.358

2.  Photochemical Resolution of a Thermally Inert Cyclometalated Ru(phbpy)(N-N)(Sulfoxide)+ Complex.

Authors:  Lucien N Lameijer; Corjan van de Griend; Samantha L Hopkins; Anne-Geert Volbeda; Sven H C Askes; Maxime A Siegler; Sylvestre Bonnet
Journal:  J Am Chem Soc       Date:  2018-12-26       Impact factor: 15.419

3.  Ruthenium-based PACT agents based on bisquinoline chelates: synthesis, photochemistry, and cytotoxicity.

Authors:  Anja Busemann; Ingrid Flaspohler; Xue-Quan Zhou; Claudia Schmidt; Sina K Goetzfried; Vincent H S van Rixel; Ingo Ott; Maxime A Siegler; Sylvestre Bonnet
Journal:  J Biol Inorg Chem       Date:  2021-08-10       Impact factor: 3.358

4.  Synthesis of O-1- O-6 Substituted Positional Isomers of d-Glucose-Thioether Ligands and Their Ruthenium Polypyridyl Conjugates.

Authors:  Lucien N Lameijer; Julien le Roy; Stefan van der Vorm; Sylvestre Bonnet
Journal:  J Org Chem       Date:  2018-10-23       Impact factor: 4.354

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.